Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2012

Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar W L, Falcone A, Danesi R

Abstract excerpt

BACKGROUND: Despite therapeutic innovations, metastatic colorectal cancer (mCRC) is still characterized by poor prognosis and few molecular markers predict the risk of progression. Polycomb group genes (PcGs) are epigenetic modifiers involved in tumor suppressor gene silencing. PcG member EZH2 mediates gene silencing through histone-H3 lysine-27 methylation. In colorectal cancer (CRC), EZH2 overexpression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Enhancer of Zeste Homolog 2 Protein

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Polycomb Repressive Complex 2

Source

Identifiers

PMID: 21926398
DOI: 10.1093/annonc/mdr387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.PMID 21926398Read ↗

Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.Semantic proximity Read ↗

Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.Semantic proximity Read ↗

Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.Semantic proximity Read ↗

Association between EZH2 Genetic Variants and Hepatocellular Carcinoma in a Chinese Han Population.Semantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features.Semantic proximity Read ↗

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomasSemantic proximity Read ↗

Mutational Analysis of EZH2 Gene in Patients with Colorectal Adenoma Reveals a Genetic Variant Associated with Risk of Malignant Transformation.Semantic proximity Read ↗

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.Semantic proximity Read ↗

Aberrations of EZH2 in cancer.Semantic proximity Read ↗

EZH2 genetic variants affect risk of gastric cancer in the Chinese Han population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.